MiNK Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Trading Plans of Our Directors and Officers
During the quarter ended September 30, 2025, none of our directors or executive officers adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each item is defined in Item 408 of Regulation S-K.
Departure of Principal Accounting Officer
On November 11, 2025, Christine M. Klaskin, Treasurer, Principal Financial Officer, and Principal Accounting Officer of the Company, informed the Company she will be retiring effective December 31, 2025. Ms. Klaskin will continue as a consultant to the Company.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.